Standing with Israel: Teva Statement Regarding the Attacks on Israel and Israeli Civilians
We are deeply saddened by the unprecedented, horrific, and brutal attacks on Israel and Israeli civilians, including women and children. As an Israeli company we condemn this appalling assault and Teva stands with Israel in this time of great loss and challenge. We are focusing now on the support, care, and the wellbeing of our employees in Israel while closely monitoring the situation.
In parallel to first providing the help and support needed for our Israeli colleagues and their families, we remain vigilant in ensuring business continuity to deliver our medicines to the millions of patients around the world who count on us.
Our employees and the patients we serve remain our utmost priority at this time. We have increased our support of emergency supply of medicines to hospitals, pharmacies, and patients in Israel and have been donating products and providing other humanitarian aid to the victims.
While the situation is evolving frequently, currently our production remains largely unaffected. We continue to maintain contingency plans with backup production locations for key products and at this time, we don’t expect a meaningful impact on our financial and operational performance. For context, Teva's production in Israel last year constituted less than 8% of our total global production in USD (and global revenues in Israel account for approximately 2% of our global revenues in USD).
Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products.
Updated: 18 October 2023